Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Maria Lozano-Rabella, Andrea García-Garijo, Jara Palomero, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 12, pp. 2250-2265
Open Access | Times Cited: 16

Showing 16 citing articles:

Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ehsan Ghorani, Charles Swanton, Sergio A. Quezada
Immunity (2023) Vol. 56, Iss. 10, pp. 2270-2295
Open Access | Times Cited: 46
What Can Ribo-Seq, Immunopeptidomics, and Proteomics Tell Us About the Noncanonical Proteome?
John R. Prensner, Jennifer G. Abelin, Leron W. Kok, et al.
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 9, pp. 100631-100631
Open Access | Times Cited: 43
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sara Sheikhlary, David Humberto Lopez, Sophia Moghimi, et al.
Biomolecules (2024) Vol. 14, Iss. 4, pp. 503-503
Open Access | Times Cited: 6
Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer
Remya Raja, Kiran K. Mangalaparthi, Anil K. Madugundu, et al.
Science Advances (2025) Vol. 11, Iss. 8
Closed Access
SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells
Melissa Bernhardt, Anne Rech, Marion Berthold, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Translation dysregulation in cancer as a source for targetable antigens
Chen Weller, Osnat Bartok, Christopher S. McGinnis, et al.
Cancer Cell (2025)
Open Access
Perspectives on the Role of “-Omics” in Predicting Response to Immunotherapy
Anna Maria Di Giacomo, Sumit K. Subudhi, Wim Vos, et al.
European Journal of Cancer (2025) Vol. 220, pp. 115393-115393
Open Access
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Weihuan Shao, Yiran Yao, Ludi Yang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy
Yuriko Minegishi, Yoshimi Haga, Koji Ueda
Cancer Science (2024) Vol. 115, Iss. 4, pp. 1048-1059
Open Access | Times Cited: 3
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies
Bernard A. Fox, Walter J. Urba, Shawn M. Jensen, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 12, pp. 2173-2175
Open Access | Times Cited: 8
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Belén Aparicio, Patrick Theunissen, Sandra Hervás‐Stubbs, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Noncanonical microprotein regulation of immunity
Cydney Nichols, Van Anh Do-Thi, Daniel Peltier
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 2905-2929
Closed Access | Times Cited: 2
What can Ribo-seq and proteomics tell us about the non-canonical proteome?
John R. Prensner, Jennifer G. Abelin, Leron W. Kok, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens
Leslie Hesnard, Catherine Thériault, M Cahuzac, et al.
Current Oncology (2024) Vol. 31, Iss. 6, pp. 3099-3121
Open Access | Times Cited: 1
The cryptic immunopeptidome in health and disease
Eralda Kina, Jean‐David Larouche, Pierre Thibault, et al.
Trends in Genetics (2024)
Closed Access | Times Cited: 1
Vaccines for cancer prevention: exploring opportunities and navigating challenges
Michele Graciotti, Lana E. Kandalaft
Nature Reviews Drug Discovery (2024)
Closed Access
MHCing the tumour’s dark genome
Miriam Saffern, Robert M. Samstein
Nature reviews. Immunology (2023) Vol. 23, Iss. 3, pp. 140-140
Open Access | Times Cited: 1
Recent advances in immunopeptidomic-based tumor neoantigen discovery
Wei Meng, Robert D. Schreiber, Cheryl F. Lichti
Advances in immunology (2023), pp. 1-36
Closed Access
Page 1

Scroll to top